According to Fortune, Dicerna Pharmaceuticals has priced its IPO of 5 million shares at between $11 and $13 per share. The stock will trade on the NASDAQ under the ticker symbol “DRNA.” Jefferies, Leerink Swann and Stifel are acting as lead underwriters. Based in Watertown, Mass., Dicerna Pharmaceuticals is a developer of RNA interference-based therapeutics. Its backers include Domain Associates, Skyline Ventures, Deerfield Management, RA Capital, Abingworth Management, Brookside Capital, S.R. One Ltd. and Oxford Bioscience Partners.